Ignite Creation Date:
2024-05-06 @ 4:04 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02443324
Status:
COMPLETED
Last Update Posted:
2022-08-18
First Post:
2015-05-11
Brief Title:
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma NSCLC Transitional Cell Carcinoma of the Urothelium or Biliary Tract Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Organization Data
Organization:
Eli Lilly and Company
Class:
INDUSTRY
Study ID:
15787
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eli Lilly and Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |